Versant Ventures, Eli Lilly, and a handful of other investors will pour $100 million into a new startup devoted to solving a thorny gene therapy challenge. Local authorities and relevant stakeholders are closely monitoring the situation as fresh developments unfold on the ground. Officials noted that further verified updates and administrative measures will be shared following a detailed review.